SHA:600867

3 stories mentioning SHA:600867Updated 13d ago

Every FINWIRES story that references SHA:600867, newest first.

Tonghua Dongbao Pharmaceutical, Nanjing King-Friend Secure US Approval for Insulin Aspart Injection; Shares Up 2%

Tonghua Dongbao Pharmaceutical (SHA:600867) said its insulin aspart injection, co-developed with Nanjing King-Friend Pharmaceutical (SHA:603707), received U.S. Food and Drug Administration biologics license application approval, according to a Tuesday filing with the Shanghai Stock Exchange.The injection is indicated to improve blood glucose control through subcutaneous injection, the filing said.Shares of Dongbao rose 2% during afternoon trading on Tuesday.

SHA:600867SHA:603707

Asia112d ago

Tonghua Dongbao Pharmaceutical Estimates Related-Party Transactions to Reach 92.6 Million Yuan in 2026

Tonghua Dongbao Pharmaceutical (SHA:600867) forecasts it will incur a total of 92.6 million yuan in routine related-party transactions in 2026, according to a Saturday filing with the Shanghai bourse.In 2025, actual related-party transactions reached 62.6 million yuan out of a projected 74 million yuan.

SHA:600867

Asia113d ago

Tonghua Dongbao Pharmaceutical Returns to Profit in 2025

Tonghua Dongbao Pharmaceutical (SHA:600867) returned to an attributable profit of 1.22 billion yuan in 2025 from an attributable loss of 142.3 million yuan in 2024, according to a Saturday filing with the Shanghai bourse.The drug company logged earnings per share of 0.62 yuan compared with a loss per share of 0.02 yuan in the previous year.Operating income grew 47% year over year to 2.95 billion yuan from 2.01 billion yuan.Shares decreased nealry 1% during the midday break on Monday.

SHA:600867

Track with the FINWIRES app suite

FolioX

Track SHA:600867 in your portfolio

WheelAI

Analyze SHA:600867 options with the wheel strategy

StockInsider

See market sentiment on SHA:600867